Integrated Analysis of Cuproptosis Regulators Reveals Prognostic Significance and Therapeutic Targets in IDH1 Mutant Glioma

Abstract

Glioma, characterized by significant heterogeneity and aggressiveness, poses a formidable therapeutic challenge. Cuproptosis, a newly identified form of regulated cell death driven by copper imbalance, has recently emerged as a pivotal factor in tumor biology. However, its role in IDH1-mutant gliomas remains poorly understood. Through comprehensive bioinformatics analysis of publicly available datasets, we identified two distinct subtypes of IDH1-mutant gliomas based on cuproptosis regulator expression profiles. Subtype G1 exhibited elevated PD-L1 expression, increased pro-tumor immune infiltration, and worse clinical outcomes, whereas subtype G2 was enriched in antitumor immune cells and associated with improved prognosis. We identified FDX1 and SLC31A1 as critical prognostic markers, with their upregulation linked to PD-L1 expression. Mechanistically, we delineated a ceRNA regulatory axis involving COX10-AS1/miR-1-3p/FDX1 and SLC31A1 that drives glioma progression. Building on these insights, we developed a prognostic risk model integrating FDX1 and SLC31A1 expression, demonstrating robust predictive accuracy for patient outcomes and potential utility in guiding individualized treatment strategies. These findings advance our understanding of the molecular landscape in IDH1-mutant gliomas and underscore the potential of cuproptosis regulators as novel therapeutic targets and biomarkers for precision oncology.

Keywords

cuproptosis / glioma / IDH1 mutation / noncoding RNA / PD-L1 / prognosis

References

[1] F.Mudassar, H.Shen, G.O’Neill, and E.Hau, “Targeting Tumor Hypoxia and Mitochondrial Metabolism With Anti-Parasitic Drugs to Improve Radiation Response in High-Grade Gliomas,” Journal of Experimental & Clinical Cancer Research 39, no. 1 (2020):208.

[2] H.Yan, D. W.Parsons, G.Jin, et al., “IDH1 and IDH2 Mutations in Gliomas,” New England Journal of Medicine 360, no. 8 (2009):765–773.

[3] L. M.Gagné, K. Boulay, I.Topisirovic, M. É.Huot, and F. A. Mallette, “Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling,” Trends in Cell Biology 27, no. 10 (2017):738–752.

[4] C. J.Pirozzi and H.Yan, “The Implications of IDH Mutations for Cancer Development and Therapy,” Nature Reviews Clinical Oncology 18, no. 10 (2021):645–661.

[5] X.Xia, X.Wang, Z.Cheng, et al., “The Role of Pyroptosis in Cancer: Pro-Cancer or Pro-‘Host’?,” Cell Death & Disease 10, no. 9 (2019):650.

[6] X.Chen, R.Kang, G.Kroemer, and D. Tang, “Broadening Horizons: The Role of Ferroptosis in Cancer,” Nature Reviews Clinical Oncology 18, no. 5 (2021):280–296.

[7] P.Tsvetkov, S.Coy, B.Petrova, et al., “Copper Induces Cell Death by Targeting Lipoylated Tca Cycle Proteins,” Science 375, no. 6586 (2022):1254–1261.

[8] X.Tong, R.Tang, M.Xiao, et al., “Targeting Cell Death Pathways for Cancer Therapy: Recent Developments in Necroptosis, Pyroptosis, Ferroptosis, and Cuproptosis Research,” Journal of Hematology & Oncology 15, no. 1 (2022):174.

[9] B.Chen, X.Zhou, L.Yang, et al., “A Cuproptosis Activation Scoring Model Predicts Neoplasm-Immunity Interactions and Personalized Treatments in Glioma,” Computers in Biology and Medicine 148 (2022):105924.

[10] M.Zulkifli, A. N.Spelbring, Y.Zhang, et al., “FDX1-Dependent and Independent Mechanisms of Elesclomol-Mediated Intracellular Copper Delivery,” Proceedings of the National Academy of Sciences 120, no. 10 (2023): e2216722120.

[11] H.Pierson, H.Yang, and S.Lutsenko, “Copper Transport and Disease: What Can We Learn From Organoids?,” Annual Review of Nutrition 39 (2019):75–94.

[12] Z. S.Razavi, V.Tajiknia, S.Majidi, et al., “Gynecologic Cancers and Non-Coding Rnas: Epigenetic Regulators With Emerging Roles,” Critical Reviews in Oncology/Hematology 157 (2021):103192.

[13] F. P.Fabrizio, A.Sparaneo, and L. A.Muscarella, “NRF2 Regulation by Noncoding RNAs in Cancers: The Present Knowledge and the Way Forward,” Cancers 12, no. 12 (2020):3621.

[14] Z.Tan, Y.Jiang, L.Liang, et al., “Dysregulation and Prometastatic Function of Glycosyltransferase C1GALT1 Modulated by cHP1BP3/miR-1-3p Axis in Bladder Cancer,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022):228.

[15] P.Deng, K.Li, F.Gu, et al., “LINC00242/miR-1-3p/G6PD Axis Regulates Warburg Effect and Affects Gastric Cancer Proliferation and Apoptosis,” Molecular Medicine 27, no. 1 (2021):9.

[16] X.Tang, Y.Wu, J.Yang, and W. Zhu, “Regulating COX10-AS1/miR-142-5p/PAICS Axis Inhibits the Proliferation of Non-Small Cell Lung Cancer,” Bioengineered 12, no. 1 (2021):4643–4653.

[17] C.Neftel, J.Laffy, M. G.Filbin, et al., “An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma,” Cell 178, no. 4 (2019):835–849.e21.

[18] A. S.Venteicher, I. Tirosh, C.Hebert, et al., “Decoupling Genetics, Lineages, and Microenvironment in IDH-Mutant Gliomas by Single-Cell Rna-Seq,” Science 355, no. 6332 (2017): eaai8478.

[19] H.Zhu, Q.Wan, J.Tan, et al., “A Novel Prognostic Signature of Cuproptosis-Related Genes and the Prognostic Value of FDX1 in Gliomas,” Frontiers in Genetics 13 (2022):992995.

[20] S.Chen, S.Zhang, Y.Yuan, et al., “Prognostic Value of Cuproptosis-Related Genes Signature and Its Impact on the Reshaped Immune Microenvironment of Glioma,” Frontiers in Pharmacology 13 (2022):1016520.

[21] Z.Zhang, B.Wang, X.Xu, and T.Xin, “Cuproptosis-Related Gene Signature Stratifies Lower-Grade Glioma Patients and Predicts Immune Characteristics,” Frontiers in Genetics 13 (2022):1036460.

[22] S.Feng, H.Liu, X.Dong, P. Du, H.Guo, and Q.Pang, “Identification and Validation of an Autophagy-Related Signature for Predicting Survival in Lower-Grade Glioma,” Bioengineered 12, no. 2 (2021):9692–9708.

[23] M. R.Ding, Y. J.Qu, X.Peng, et al., “Pyroptosis-Related Prognosis Model, Immunocyte Infiltration Characterization, and Competing Endogenous RNA Network of Glioblastoma,” BMC Cancer 22, no. 1 (2022):611.

[24] S.Feng, X.Liang, J.Li, et al., “Immunogenic Cell Death Related Risk Model to Delineate Ferroptosis Pathway and Predict Immunotherapy Response of Patients With GBM,” Frontiers in Immunology 13 (2022):992855.

[25] L.Zhou, Z.Jiang, Z.Shi, et al., “New Autophagy-Ferroptosis Gene Signature Predicts Survival in Glioma,” Frontiers in Cell and Developmental Biology 9 (2021):739097.

[26] Z. K.Ballas, “The 2018 Nobel Prize in Physiology or Medicine: An Exemplar of Bench to Bedside in Immunology,” Journal of Allergy and Clinical Immunology 142, no. 6 (2018):1752–1753.

[27] S.Xu, L.Tang, X.Li, F.Fan, and Z.Liu, “Immunotherapy for Glioma: Current Management and Future Application,” Cancer Letters 476 (2020):1–12.

[28] P.Sharma, S.Hu-Lieskovan, J. A.Wargo, and A.Ribas, “Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy,” Cell 168, no. 4 (2017):707–723.

[29] H.Zhang, T. U.Ahearn, J.Lecarpentier, et al., “Genome-Wide Association Study Identifies 32 Novel Breast Cancer Susceptibility Loci From Overall and Subtype-Specific Analyses,” Nature Genetics 52, no. 6 (2020):572–581.

[30] W.Zhang, S.Yao, H.Huang, et al., “Molecular Subtypes Based on Ferroptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Lung Adenocarcinoma,” Oncoimmunology 10, no. 1 (2021):1959977.

[31] Z. G.Fridlender, J. Sun, S.Kim, et al., “Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: ‘N1’ Versus ‘N2’ TAN,” Cancer Cell 16, no. 3 (2009):183–194.

[32] L.Andzinski, N.Kasnitz, S.Stahnke, et al., “Type I IFNs Induce Anti-Tumor Polarization of Tumor Associated Neutrophils in Mice and Human,” International Journal of Cancer 138, no. 8 (2016):1982–1993.

[33] J. Y.Sagiv, J.Michaeli, S.Assi, et al., “Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer,” Cell Reports 10, no. 4 (2015):562–573.

[34] F.Winkler, “In Glioma, All Endothelial Cells Are Not Created the Same,” Neuro-Oncology 23, no. 6 (2021):863–864.

[35] Y.Qin, Y.Liu, X.Xiang, et al., “Cuproptosis Correlates With Immunosuppressive Tumor Microenvironment Based on Pan-Cancer Multiomics and Single-Cell Sequencing Analysis,” Molecular Cancer 22, no. 1 (2023):59.

[36] M. L.Broekman, S. L. N. Maas, E. R.Abels, T. R.Mempel, A. M.Krichevsky, and X. O.Breakefield, “Multidimensional Communication in the Microenvirons of Glioblastoma,” Nature Reviews Neurology 14, no. 8 (2018):482–495.

[37] B.Sun, P.Ding, Y.Song, et al., “FDX1 Downregulation Activates Mitophagy and the PI3K/AKT Signaling Pathway to Promote Hepatocellular Carcinoma Progression by Inducing ROS Production,” Redox Biology 75 (2024):103302.

[38] M.Xie, B.Cheng, S.Yu, et al., “Cuproptosis-Related MiR-21-5p/FDX1 Axis in Clear Cell Renal Cell Carcinoma and Its Potential Impact on Tumor Microenvironment,” Cells 12, no. 1 (2022):173.

[39] L.Guowei, L.Xiufang, X.Qianqian, and J.Yanping, “The FDX1 Methylation Regulatory Mechanism in the Malignant Phenotype of Glioma,” Genomics 115, no. 2 (2023):110601.

[40] Z.Yu, R.Zhou, Y.Zhao, et al., “Blockage of SLC31A1-Dependent Copper Absorption Increases Pancreatic Cancer Cell Autophagy to Resist Cell Death,” Cell Proliferation 52, no. 2 (2019): e12568.

[41] S. Z.Deng, M. F.Lai, Y. P.Li, C. H. Xu, H. R.Zhang, and J. G.Kuang, “Human Marrow Stromal Cells Secrete MicroRNA-375-Containing Exosomes to Regulate Glioma Progression,” Cancer Gene Therapy 27, no. 3–4 (2020):203–215.

[42] Q.Huang, L.Zhan, H.Cao, et al., “Increased Mitochondrial Fission Promotes Autophagy and Hepatocellular Carcinoma Cell Survival Through the Ros-Modulated Coordinated Regulation of the NFKB and TP53 Pathways,” Autophagy 12, no. 6 (2016):999–1014.

[43] S.Dong, S.Liang, Z.Cheng, et al., “ROS/PI3K/Akt and Wnt/β-Catenin Signalings Activate HIF-1α-Induced Metabolic Reprogramming to Impart 5-fluorouracil Resistance in Colorectal Cancer,” Journal of Experimental & Clinical Cancer Research 41, no. 1 (2022):15.

[44] H.Cai, L.Yan, N.Liu, M. Xu, and H.Cai, “IFI16 Promotes Cervical Cancer Progression by Upregulating PD-L1 in Immunomicroenvironment Through STING-TBK1-NF-kB Pathway,” Biomedicine & Pharmacotherapy 123 (2020):109790.

[45] G.Konstantopoulos, D. Leventakou, D. R.Saltiel, et al., “HPV16 E6 Oncogene Contributes to Cancer Immune Evasion by Regulating PD-L1 Expression Through a miR-143/HIF-1a Pathway,” Viruses 16, no. 1 (2024):113.

[46] Q.Xue, R.Kang, D. J.Klionsky, D.Tang, J.Liu, and X.Chen, “Copper Metabolism in Cell Death and Autophagy,” Autophagy 19, no. 8 (2023):2175–2195.

[47] G. G.Wang, Y.Wang, S. L.Wang, and L. C. Zhu, “Down-Regulation of CX43 Expression by miR-1 Inhibits the Proliferation and Invasion of Glioma Cells,” Translational Cancer Research 11, no. 11 (2022):4126–4136.

[48] L.Liu, X.Li, H.Wu, Y.Tang, X.Li, and Y.Shi, “The COX10-AS1/miR-641/E2F6 Feedback Loop Is Involved in the Progression of Glioma,” Frontiers in Oncology 11 (2021):648152.

[49] F.Varghese, A. B.Bukhari, R.Malhotra, and A.De, “IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples,” PLoS One 9, no. 5 (2014): e96801.

[50] P.Jiang, S.Gu, D.Pan, et al., “Signatures of T Cell Dysfunction and Exclusion Predict Cancer Immunotherapy Response,” Nature Medicine 24, no. 10 (2018):1550–1558.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm – Future Medicine published by John Wiley & Sons Australia, Ltd on behalf of Sichuan International Medical Exchange & Promotion Association (SCIMEA).